The global geographic atrophy market size is expected to be valued at US$ 1.2 billion in 2026 and projected to reach US$ 2.6 billion by 2033, growing at a CAGR of 11.3% between 2026 and 2033.

The market's robust growth is fundamentally driven by the landmark regulatory approvals of first-in-class complement inhibitor therapies, specifically Syfovre (Apellis Pharmaceuticals) and Izervay (Astellas Pharma/Iveric Bio), which have transformed the previously untreatable geographic atrophy (GA) landscape.

Compounding this, the rapidly ageing global population is expanding the addressable patient pool: the World Health Organization (WHO) projects that the number of people aged 60 years or older will reach 2.1 billion by 2050, significantly increasing the prevalence of age-related macular degeneration (AMD) and its advanced form, GA, across all geographies.

Drivers - First-in-Class Complement Inhibitor Approvals Unlocking a Previously Untreatable Patient Population

The approval of complement pathway inhibitors has been the single most transformative catalyst in the geographic atrophy market. In February 2023, the U.S. Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan, Apellis Pharmaceuticals) as the first-ever treatment for GA secondary to AMD, ending decades of therapeutic nihilism for a disease affecting over 5 billion patients in the United States alone, per estimates from the BrightFocus Foundation. This was followed by the FDA approval of Izervay (avacincaptad pegol, Astellas Pharma) in August 2023. These milestone approvals have created a de novo commercial market, driven physician and patient awareness, and catalysed competitive pipeline investment establishing complement inhibition as the foundational treatment paradigm for GA through the forecast period.

Rapidly Ageing Global Population Expanding the GA Patient Pool

Geographic atrophy is intrinsically an age-related condition, with incidence rising sharply among individuals over 65 years. The WHO estimates that the global population aged 65 and over will double from 703 million in 2019 to 1.5 billion by 2050. In high-income nations, this demographic shift is already translating into a growing burden of AMD and advanced GA. The American Academy of Ophthalmology (AAO) projects that AMD cases in the U.S. will reach $5.44 billion by 2050, up from an estimated $2.07 billion in 2010.

In Asia, particularly in Japan and China, which have some of the world's fastest-ageing populations, demand for GA diagnostics and therapies is poised to expand materially, broadening the geographic revenue opportunity for market participants.

Restraints - High Therapy Costs and Reimbursement Barriers Limiting Patient Access

The high cost of complement inhibitor therapies poses a formidable access challenge. Syfovre carries a list price of approximately US$ 2,190 per monthly injection and US$ 3,280 for every-other-month dosing, as reported by Apellis Pharmaceuticals. Securing comprehensive insurance and government reimbursement across diverse healthcare systems, particularly in Europe and the Asia Pacific, remains protracted and uncertain. These reimbursement hurdles constrain real-world patient uptake relative to the diagnosed population, thereby limiting the rate at which companies can convert addressable patient pools into commercial revenue.

Chronic Adverse Event Profile and Injection Burden Dampening Adoption

Safety signals have emerged as a material concern for GA complement inhibitors. Post-marketing data for Syfovre revealed cases of occlusive retinal vasculitis, a rare but severe adverse event, prompting updated prescribing information from the FDA in mid-2023. Additionally, the requirement for recurring intravitreal injections monthly or bimonthly places a significant burden on patients and retinal practices alike. Per the American Society of Retina Specialists (ASRS), injection fatigue is a documented driver of non-adherence in retinal diseases, which risks undermining long-term therapeutic outcomes and commercial durability for approved GA treatments.

Opportunities - Gene Therapy and Stem Cell Platforms Offering Potentially Curative, Long-Duration Outcomes

Gene therapy and stem cell-based approaches represent a paradigm-shifting opportunity in the geographic atrophy market, offering the prospect of disease modification or reversal with single or infrequent administrations addressing the durability and adherence limitations of current complement inhibitors. Gyroscope Therapeutics (acquired by Novartis) is advancing GT005, an investigational AAV-based complement factor I gene therapy, currently in Phase 2 trials.

Lineage Cell Therapeutics is evaluating OpRegen, a retinal pigment epithelium (RPE) cell replacement therapy co-developed with Genentech/Roche, which has demonstrated evidence of GA lesion repair in early-stage trials. If approved, such therapies could redefine the GA treatment standard, commanding premium pricing and capturing significant market share from the current intravitreal injection paradigm through 2033.

Specialty Ophthalmology Clinics and ASCs Emerging as High-Growth Care Settings

As GA therapy adoption scales, specialty ophthalmology clinics and ambulatory surgical centers (ASCs) are emerging as the fastest-growing end-user segment offering an important commercial expansion opportunity. Unlike hospital-based administration, these settings offer optimized throughput for high-volume intravitreal injection procedures, lower overhead costs, and superior patient experience. According to the American Society of Cataract and Refractive Surgery (ASCRS), over 60% of ophthalmic surgeries in the U.S. are performed in ASC settings.

Pharmaceutical companies and device manufacturers that build targeted outreach, medical education, and patient support programs tailored to retinal specialty practices stand to disproportionately benefit from this channel shift, particularly as GA treatment guidelines solidify and patient identification programs improve diagnosis rates in community ophthalmology settings.

End-user Insights

Hospitals represent the leading end-user segment in the geographic atrophy market, capturing approximately 42% of total revenues in 2025. Hospital-based retinal departments and academic medical centers are primary sites for GA diagnosis, treatment initiation, and management of complex or high-risk patients, particularly those with comorbid systemic conditions. Large hospital networks command formulary access, enabling faster uptake of newly approved GA therapies.

According to the Centers for Medicare & Medicaid Services (CMS), hospital outpatient departments are among the most common settings for retinal injection procedures in the United States, where Medicare covers a substantial proportion of GA patients, given the disease's strong association with advanced age. This payer concentration reinforces the hospital channel's commercial significance.

North America Geographic Atrophy Market Trends and Insights

North America leads the geographic atrophy market due to the high disease prevalence, early adoption of complement inhibitor therapies, strong ophthalmology infrastructure, and high healthcare spending. The United States alone accounts for the largest share of diagnosed GA cases in the 7MM, supported by advanced retinal imaging and reimbursement systems. According to epidemiology studies, the U.S. contributes the highest burden of GA cases in developed markets, while Canada shows steady growth driven by aging demographics and improved screening.

High uptake of therapies such as SYFOVRE and IZERVAY further strengthens regional dominance. The region benefits from strong R&D investments and FDA-led rapid approvals, making it the most mature GA treatment market globally.

U.S. Geographic Atrophy Market Trends and Insights

The U.S. is the leading country in North America and is expected to reach ~US$ 0.58 billion (2026 GA market contribution). It has the highest number of Geographic Atrophy cases globally within developed regions, driven by an aging population (over 80 million aged 65+). High screening rates, Medicare coverage, and early access to FDA-approved therapies drive rapid adoption. The U.S. also hosts major clinical trials for complement inhibitors and gene therapies, reinforcing its dominance in ophthalmology innovation.

Canada Geographic Atrophy Market Trends and Insights

Canada is a fast-developing GA market expected to grow at ~12% CAGR. The growth is supported by increasing awareness of age-related macular degeneration (AMD), expanding retinal specialty clinics, and government-funded healthcare access. Canada’s aging population and rising diagnostic penetration are improving early detection rates, leading to higher treatment uptake, especially in urban centers like Toronto and Vancouver.

Europe Geographic Atrophy Market Trends and Insights

Europe holds a strong position due to its large elderly population, high prevalence of AMD, strong clinical research ecosystem, and supportive regulatory frameworks. Epidemiological data show that EU4 + UK together account for nearly ~955,000 GA cases, with Germany and France contributing the highest burden. The presence of well-established ophthalmology systems and early participation in clinical trials supports steady adoption of new therapies. Europe also plays a key role in evaluating long-term safety and efficacy of complement inhibitor therapies and emerging gene therapies.

Germany Geographic Atrophy Market Trends and Insights

Germany is the leading European country and is expected to reach ~US$ 0.32 billion (2026 GA market contribution). It has one of the highest elderly populations in Europe and a strong healthcare reimbursement system. Germany also leads in retinal research and clinical trials for complement inhibitors and regenerative therapies. High availability of ophthalmology specialists supports early diagnosis and treatment adoption.

France Geographic Atrophy Market Trends and Insights

France is the fastest-growing major European market with ~12.7% CAGR. Growth is driven by increasing life expectancy, rising AMD prevalence, and government-supported vision care programs. France is also expanding retinal imaging infrastructure, improving early detection of Geographic Atrophy, especially in aging rural populations.

Asia Pacific Geographic Atrophy Market Trends and Insights

Asia Pacific is the fastest-growing regional market due to rapid population aging, rising awareness of retinal diseases, and improving healthcare infrastructure. Although GA prevalence is lower than in Western countries (Asia ~0.21% vs USA ~1.47%), the absolute patient pool is expanding significantly due to demographic shifts. Countries like China, Japan, and India are investing heavily in ophthalmology infrastructure and retinal diagnostics. Growth is also supported by increasing adoption of advanced imaging technologies such as OCT and FAF in urban hospitals.

China Geographic Atrophy Market Trends and Insights

China is the leading APAC country and is expected to reach ~US$ 210 million (2026 GA market contribution). The country has the largest aging population globally, with a rapidly increasing AMD burden. Expansion of tertiary eye hospitals, rising healthcare spending, and government initiatives for elderly vision care are driving growth in Geographic Atrophy diagnosis and treatment access.

India Geographic Atrophy Market Trends and Insights

India is the fastest-growing APAC country with ~14% CAGR. Growth is driven by a rapidly aging population, increasing diabetic and ocular disease burden, and expanding private ophthalmology networks. Awareness programs and affordability-driven access improvements are increasing diagnosis rates, especially in tier-1 and tier-2 cities.

The geographic atrophy market is currently highly concentrated, with Apellis Pharmaceuticals (Syfovre) and Astellas Pharma (Izervay) holding a near-duopoly in the approved therapeutics space as of 2025. The market is transitioning from nascency to early growth, with differentiation centered on clinical efficacy, safety profile, injection frequency convenience, and payer access strategies. Key pipeline players including Novartis (GT005 gene therapy), Genentech/Roche (OpRegen), and Boehringer Ingelheim (BI 1467335) are advancing investigational therapies, and their entry is expected to progressively fragment the competitive landscape. Strategic partnerships and licensing deals are the dominant business model for pipeline-stage companies.

Key Developments:

• May 2026: Biogen completed its acquisition of Apellis Pharmaceuticals in a $5.6 billion deal, marking a major expansion of its presence in ophthalmology, immunology, and rare diseases. The transaction brought Apellis’ commercial portfolio under Biogen’s ownership, including its key drug for Geographic Atrophy, SYFOVRE®, along with the rare disease therapy Empaveli.
• January 2025: Australia’s Therapeutic Goods Administration (TGA) approved the first treatment for geographic atrophy (GA), marking a major milestone in the management of advanced dry age-related macular degeneration. The regulator approved SYFOVRE® (pegcetacoplan), developed by Apellis Pharmaceuticals, making Australia one of the first countries outside the United States to authorize a therapy specifically designed to slow the progression of GA.